1d
Pharmaceutical Technology on MSNVivace closes $35m in Series D for cancer drug developmentVivace Therapeutics has closed $35m in a Series D financing round to support the clinical development of its cancer drug ...
Driven Platform to Shape Future of Recruiting NEW YORK, March 3, 2025 /PRNewswire/ -- HeyMilo, an AI-powered candidate screening platform, today announced $2.2 million in seed funding. The round, led ...
Financing Led by RA Capital Management with Participation from Other Existing Investors Canaan Partners and Cenova Capital VT3989 is the Only TEAD Autopalmitoylation Inhibitor ...
Vivace Therapeutics Inc. closed a $35 million series D round led by RA Capital Management, an existing investor, and including other backers already on board: Canaan Partners and Cenova Capital.
SAN FRANCISCO, Feb. 18, 2025 /PRNewswire/ -- Valid, the AI-enabled ad agency transforming digital advertising, today announced $5.5 million in seed funding led by Canaan Partners. Neo, J Ventures ...
Canaan Partners (Rowayton, Connecticut and Menlo Park, Calif.) led the investment, with Series A investor New Enterprise Associates (Menlo Park) participating. Jim Furnivall, general partner of Canaan ...
Canaan CAN has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table summarizes their recent ratings ...
The round, led by Canaan Partners, underscores the growing demand for innovative technologies that streamline recruitment and unlock efficiencies in talent acquisition. Additional participation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results